Further studies of the mineralocorticoid activity of 19-oxo-deoxycorticosterone.
Antinatriuretic and kaliuretic activities of 19-oxo-deoxycorticosterone (19-oxo-DOC) were measured in male adrenalectomized rats and compared with those of aldosterone. No significant effects of 19-oxo-DOC or aldosterone were observed in the lag period (i.e. the first hour post injection). In the subsequent 2 h, rats injected with 25 micrograms 19-oxo-DOC excreted less than half the sodium and more than twice the potassium compared to rats injected with vehicle alone. Overall mineralocorticoid activity (based on changes in urinary Na+/K+), antinatriuretic activity (based on changes in urinary Na+/creatinine) and kaliuretic activity (based on changes in urinary K+/creatinine) of 19-oxo-DOC were all in the range of 1:100th-1:200th that of aldosterone. These results are not in agreement with a recent report suggesting that 19-oxo-DOC possesses antinatriuretic activity but no kaliuretic activity.
D000450:Aldosterone / Q000494:pharmacology; D000818:Animals; D003900:Desoxycorticosterone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000502:physiology; D008297:Male; D008901:Mineralocorticoids / Q000502:physiology*; D009318:Natriuresis / Q000187:drug effects; D011188:Potassium / Q000652:urine; D051381:Rats; D011919:Rats, Inbred Strains
D008901:Mineralocorticoids; D003900:Desoxycorticosterone; D000450:Aldosterone; C033576:19-oxo-deoxycorticosterone; D011188:Potassium